The Technical Analyst
Revelation Biosciences, [REVB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Revelation Biosciences, Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.39% $2.14
America/New_York / 25 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 3.49 mill |
| EPS: | -0.530 |
| P/E: | -4.04 |
| Earnings Date: | May 20, 2024 |
| SharesOutstanding: | 1.633 mill |
| Avg Daily Volume: | 0.406 mill |
| RATING 2024-04-25 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Sell | |
| P/E: | Neutral | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
| Gr.Profit | n/a | n/a | n/a | n/a | ||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.04 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.69x |
| Company: PE -4.04 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 1.741 - 2.54 ( +/- 18.64%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-12-08 | Tidmarsh George F | Sell | 27 771 | Common Stock |
| 2023-10-16 | Tidmarsh George F | Sell | 1 845 | Common Stock |
| 2023-10-16 | Tidmarsh George F | Sell | 10 957 | Common Stock |
| 2023-09-27 | Chawla Lakhmir S | Buy | 0 | |
| 2023-09-28 | Tidmarsh George F | Sell | 1 429 | Common Stock |
| INSIDER POWER |
|---|
| -12.40 |
| Last 48 transactions |
| Buy: 316 523 | Sell: 2 020 596 |
Forecast:
16:00 - $2.14
Live Trading Signals (every 1 min)
Forecast
1: 15:53 - $2.13
Forecast 2: 16:00 - $2.14
Forecast 3: 16:00 - $2.14
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.14 (2.39% ) |
| Volume | 0.0084 mill |
| Avg. Vol. | 0.406 mill |
| % of Avg. Vol | 2.07 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For REVB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
REVB
Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
Latest Press Releases
2024-03-22 16:15:00 - Press Release
Revelation Biosciences, Inc. Announces Financial Results For The Three And Twelve Months Ended December 31, 2023
San diego--(business wire)-- #biotechnews--revelation biosciences, inc. (nasdaq: revb) (the “company” or “revelation”), a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today reported its three and twelve months ended december 31, 2023 financial results. corporate highlights completed a $6.2 million public offering. commencement of first in human phase 1 clinical study of gemini at the beginning of march. oral prese.
2024-03-13 09:00:00 - Press Release
Revelation Biosciences Inc. Gives Oral Presentation At Advances In Critical Care Nephrology (aki & Crrt 2024)
San diego--(business wire)-- #biotechnews--revelation biosciences inc. (nasdaq: revb) (the “company” or “revelation”) a clinical-stage life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today new preclinical data on the potential therapeutic benefit of gemini for the prevention of acute kidney injury (aki) that was presented at the international conference on advances in critical care nephrology (aki & crrt 2024) taking.
2024-02-13 09:00:00 - Press Release
Revelation Biosciences Inc. Receives Invitation To Give An Oral Presentation At The 29th International Conference On Advances In Critical Care Nephrology (aki & Crrt 2024)
San diego--(business wire)-- #biotechnews--revelation biosciences inc. (nasdaq: revb) (the “company” or “revelation”), announced today that, as part of a limited number of accepted abstract authors, the company was invited to give an oral presentation of new preclinical data on the potential therapeutic benefit of gemini for the prevention of acute kidney injury (aki) at the 29th international conference on advances in critical care nephrology taking place in san diego from march 12-15, 2024. gemini is the co.
2024-02-05 16:41:00 - Press Release
Revelation Biosciences Inc. Announces Closing Of $6.2 Million Public Offering
San diego--(business wire)-- #biotechnews--revelation biosciences inc. (nasdaq: revb) (the “company” or “revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the closing on february 5, 2024 of its previously announced public offering of 128,470 shares of its common stock and 1,236,530 pre-funded warrants to purchase shares of common stock, together with warrants to purchase up to 2,730,000 shares of its c.
2024-02-01 06:00:00 - Press Release
Revelation Biosciences Inc. Announces Pricing Of $6.2 Million Public Offering
San diego--(business wire)-- #biotechnews--revelation biosciences inc. (nasdaq: revb) (the “company” or “revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, today announced the pricing of a public offering of 1,365,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 2,730,000 shares of its common stock at an offering price to the public of $4.53 per share and associated.
Latest News
2022-10-26 06:00:00 - PennyStocks
Buying Penny Stocks? 3 Technical Indicators to Use
Use these technical indicators for trading penny stocks right now The post Buying Penny Stocks? 3 Technical Indicators to Use appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-10-25 14:01:11 - InvestorPlace
Revelation Biosciences (REVB) Stock Soars 70% on Positive Pre-Clinical Data
One of the more interesting movers in today's market is life sciences company Revelation Biosciences (NASDAQ: REVB ). After announcing positive pre-clinical data for the company's treatment of chronic kidney disease, REVB stock has surged more than 70% in early afternoon trading.
2022-10-25 11:02:29 - PennyStocks
3 Hot Penny Stocks To Buy Under $3 With Must Read News
Penny stocks to watch with news today. The post 3 Hot Penny Stocks To Buy Under $3 With Must Read News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-09-02 20:22:13 - 24/7 Wall Street
These Are The Five Best And Worst Performing Penny Stocks Of 2022 (So Far)
Penny stocks are shares that usually trade at $5 or less. These stocks are mostly of small companies that usually trade over-the-counter (OTC).
2022-08-09 14:11:51 - PennyStocks
Penny Stocks To Watch: Why REVB, RVPH, BARK, and GRAY Stock Are Moving
Hot penny stocks to watch this week. The post Penny Stocks To Watch: Why REVB, RVPH, BARK, and GRAY Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-07-28 11:30:26 - PennyStocks
Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch
Biotech penny stocks to watch this week. The post Best Penny Stocks To Buy As Recession Begins?
2022-06-30 13:02:28 - InvestorPlace
Revelation Biosciences (REVB) Stock Soars 120%
REVB stock is soaring 120%, but no news explains the rally. The firm recently finished dosing patients for a trial of its hay fever drug.
2022-06-30 09:29:38 - PennyStocks
3 Penny Stocks To Watch While The Stock Market Is Down
Penny stocks for your watch list with the stock market down today. The post 3 Penny Stocks To Watch While The Stock Market Is Down appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-04-20 18:30:00 - PennyStocks
Trending Penny Stocks For Your May 2022 Watchlist
Are these trending penny stocks on your watchlist for next month? The post Trending Penny Stocks For Your May 2022 Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-03-17 17:16:24 - PennyStocks
Penny Stocks That Could Explode in April 2022? 3 to Watch
Can these penny stocks explode next month? The post Penny Stocks That Could Explode in April 2022?